On October 31, 2024, the European Commission (the Commission) delivered its long-awaited decision in the Teva Copaxone case (which was published on April 8, 2025). Teva, a global pharmaceutical company, was fined EUR 462.6...more
4/17/2025
/ Abuse of Dominance ,
Antitrust Violations ,
Drug Pricing ,
EU ,
European Commission ,
Generic Drugs ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Teva Pharmaceuticals
On July 22, 2024, the European Commission (EC) accepted commitments proposed by Vifor Pharmaceuticals to address disparagement concerns under Article 102 TFEU. This is the EC’s first pure disparagement case and its second...more
8/21/2024
/ Competition ,
Disparagement ,
EU ,
European Commission ,
Financial Conduct Authority (FCA) ,
Investigations ,
Patents ,
Pharmaceutical Industry ,
Teva Pharmaceuticals ,
Treaty on the Functioning of the European Union (TFEU) ,
UK ,
UK Competition and Markets Authority (CMA)